pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Clinical outcomes of major cardiac and cerebrovascular events among patients with clopidogrel, cilostazol and sarpogrelate

Clopidogrel (n=906)Cilostazol (n=79)Sarpogrelate (n=64)p-value
MACCEPatient with event(n)114(12.58)12(15.19)6(9.38)0.581
Patient-year(PYs)3079.00248.79261.79
Incidence rate per 100 PYs4.426.034.2

DeathPatient with event(n)16(1.77)1(1.27)1(1.56)1.000
Patient-year(PYs)3403.31287.97288.45
Incidence rate per 100 PYs0.470.350.35

MIPatient with event(n)70(7.73)7(8.86)2(3.13)0.362
Patient-year(PYs)3193.9267.39283.92
Incidence rate per 100 PYs2.192.620.7

StrokePatient with event(n)35(3.86)4(5.06)3(4.69)0.685
Patient-year(PYs)3317.42274.93280.04
Incidence rate per 100 PYs1.061.451.07

PVDPatient with event(n)28(3.09)3(3.80)5(7.81)0.125
Patient-year(PYs)3351.59282.42274.74
Incidence rate per 100 PYs0.841.061.82

MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; PVD, peripheral vascular disease

Korean J Clin Pharm 2019;29:254-66 https://doi.org/10.24304/kjcp.2019.29.4.254
© 2019 Korean J Clin Pharm